🩺 Record Detail

Patient Info

Name: Unknown
Age: Unknown
Date: 2026-09-24 21:00:53

Transcript

[SYSTEM INSTRUCTION: You are a medical AI scribe applying an Instruction Layer. 1. Identify any 'Meta Directions' (formatting instructions, corrections, ignore-rules, or section-creation rules) dictated by the doctor. 2. Do NOT treat Meta Directions as clinical facts. Instead, use them as strict rules to shape the final note. 3. Apply formatting instructions (e.g., bullet points, conciseness). 4. Apply correction instructions (e.g., overriding a pain score or symptom). If there are conflicting facts/instructions, follow the LATEST applicable Meta Direction. 5. Apply ignore instructions (e.g., omit specific brand names). 6. Move information to the section explicitly requested. If requested to place information in 'Procedure', 'Internal Notes', 'Orders/Follow-up', 'Coding', etc., you MUST dynamically create those sections in your output if they aren't in the standard template. 7. Do not invent unsupported clinical information. Preserve existing normal dictation behavior. 8. Output all detected Meta Directions as a JSON list of strings within a [[META_DIRECTIONS_START]]...[[META_DIRECTIONS_END]] block at the very end of your response.
9. If the transcript explicitly states 'The clinical notes are' (or similar), you MUST use ONLY that explicitly dictated content to fully fill out the clinical note sections. Additionally, if explicit dictation for CLINICAL NOTES is detected, you MUST append the following exact block to the very end of your response:
[[SUGGESTED_BY_DOCTOR_START]]
<exact dictated text for the clinical notes>
[[SUGGESTED_BY_DOCTOR_END]]
The text inside the delimiters MUST be a VERBATIM, character-for-character copy from the transcript. Do NOT fix typos, do NOT reformat, and do NOT correct medical terms. Do NOT output 'Suggested by Doctor:' in the main text. Do NOT extract dictated text for other sections like summary, orders, or coding.]

[TRANSCRIPT]
Okay, checking in a patient now, this is Priya Nandakumar, date of birth
January 19th, 1991. Insurance is Pacific Blue Cross, member ID PBC9012734,
group 4410. She's been here before, this is a follow-up. Confirmed her
address is unchanged, copay of 20 dollars collected.

This is her second visit with us. First visit about eight weeks ago she
came in with fatigue and joint pain, we ran some initial labs, ANA came
back positive at that time, and we started her on hydroxychloroquine 200
milligrams twice daily while we worked up the rest of the picture.

Chief complaint today, follow-up on fatigue and joint pain, plus she's
now noticing a rash across her cheeks and nose that comes and goes,
especially after being out in the sun.

History: she says the joint pain is still there, mostly in her hands and
wrists, some mornings worse than others. Fatigue hasn't really improved.
The facial rash started about three weeks ago, she describes it as red,
flat, doesn't really itch, and it seems to flare after sun exposure, which
she noticed pretty clearly last weekend after a day at the beach. No
mouth sores that she's noticed, no chest pain, no shortness of breath, no
hair loss that she's aware of, though I should ask her to look more
carefully at that.

Exam. Vitals stable, blood pressure 118 over 76, heart rate 72. Skin
exam, there's an erythematous rash across both cheeks and the bridge of
the nose, spares the nasolabial folds, no scarring, no scaling. Joint
exam, mild synovitis in the MCPs bilaterally, no deformity. No oral
ulcers on exam today. Lungs clear, heart sounds normal, no rub.

Labs reviewed from today's draw, well actually these were drawn last
week and resulted this morning. ANA still positive, titer 1 to 640,
speckled pattern. Anti-dsDNA is positive. Complement levels, C3 and C4,
are both low. CBC shows mild leukopenia, white count 3.2. Urinalysis is
clean, no protein, no blood.

So let me think through this for a second. Positive ANA at high titer,
positive anti-dsDNA, low complement, leukopenia, malar rash that's
photosensitive, and inflammatory arthritis. That's, that's actually a
pretty classic constellation. I was originally thinking this could just
be an undifferentiated connective tissue disease given how nonspecific
the first visit presentation was, fatigue and joint pain alone could be
a dozen things. But the dsDNA and low complement really push this toward
lupus specifically rather than something like Sjogren's or early
rheumatoid, which don't typically give you that dsDNA and complement
pattern together. The clean urinalysis is reassuring, at least there's
no evidence of renal involvement right now, so I don't think we're
dealing with lupus nephritis at this point, but that's definitely
something I want to keep watching closely given how often it shows up
later even when it's not there at diagnosis.

Assessment: systemic lupus erythematosus, with malar rash, arthritis,
and serologic findings meeting criteria. Diagnosis code M32.10. Also
noting leukopenia associated with the underlying disease, code D72.819.

Plan: continuing hydroxychloroquine 200 milligrams twice daily, that
stays the same. Given the joint symptoms aren't controlled and there's
now more systemic involvement, adding a low dose of prednisone, 10
milligrams daily, short term, while we see how things trend. Strict sun
protection counseling given the photosensitivity, recommend SPF 50 daily
and sun avoidance during peak hours. Ordering repeat complement levels
and anti-dsDNA in six weeks to track disease activity, along with a
urinalysis with microscopy to keep monitoring for any early kidney
involvement, that's going to be CPT 82525 for complement, 86225 for
dsDNA antibody, and 81001 for the urinalysis with microscopy.

Given this is a new lupus diagnosis with multi-system involvement, I
want to get rheumatology formally on board for co-management going
forward rather than me running this alone, so referring to rheumatology.

For the patient, I'll explain that her labs and symptoms together point
to lupus, which explains the joint pain, fatigue, and the rash. We're
going to keep her on the current medication and add a short course of a
steroid to help calm things down faster while that other medication
builds up its effect. Sun protection is really important given her skin
is reacting to it. We'll recheck her bloodwork in six weeks and she'll
also be seeing a rheumatologist who will help manage this alongside me
going forward.

Follow-up: bring her back in four weeks to check how she's tolerating
the prednisone and reassess symptoms, sooner if anything concerning
comes up like swelling, blood in urine, or chest pain. Front desk,
please schedule her for follow-up on October 22nd. Also have someone
call in two weeks just to check she's doing okay on the new medication
and confirm the rheumatology referral appointment got booked.

Clinical Notes

SOAP Clinical Note

Subjective

Patient: Priya Nandakumar, DOB: January 19th, 1991. This is a follow-up visit for fatigue and joint pain. The patient reports persistent joint pain, primarily in the hands and wrists, with some mornings being worse. Fatigue remains unchanged. She has developed a rash across her cheeks and nose, which flares after sun exposure, noted clearly after a day at the beach. The rash is described as red, flat, and non-itchy. No mouth sores, chest pain, shortness of breath, or hair loss reported.

Objective

  • Vitals: Blood pressure 118/76 mmHg, heart rate 72 bpm.
  • Skin exam: Erythematous rash across cheeks and nose, sparing nasolabial folds, no scarring or scaling.
  • Joint exam: Mild synovitis in MCPs bilaterally, no deformity.
  • No oral ulcers.
  • Lungs: Clear.
  • Heart: Normal sounds, no rub.
  • Labs:
  • ANA positive, titer 1:640, speckled pattern.
  • Anti-dsDNA positive.
  • Low complement levels (C3 and C4).
  • CBC shows mild leukopenia, white count 3.2.
  • Urinalysis: Clean, no protein or blood.

Assessment

Systemic lupus erythematosus (SLE) with malar rash, arthritis, and serologic findings meeting criteria. Diagnosis code M32.10. Leukopenia associated with underlying disease, code D72.819.

Plan

  • Continue hydroxychloroquine 200 mg twice daily.
  • Add prednisone 10 mg daily, short term.
  • Counsel on strict sun protection: SPF 50 daily and sun avoidance during peak hours.
  • Order repeat complement levels and anti-dsDNA in six weeks to monitor disease activity.
  • Order urinalysis with microscopy to monitor for kidney involvement.
  • Refer to rheumatology for co-management.
  • Explain to the patient the diagnosis of lupus and the treatment plan.
  • Follow-up in four weeks to assess prednisone tolerance and symptoms, sooner if concerning symptoms arise.
  • Schedule follow-up on October 22nd.
  • Call in two weeks to check on medication tolerance and confirm rheumatology appointment.

Orders

  • CPT 82525 for complement levels.
  • CPT 86225 for dsDNA antibody.
  • CPT 81001 for urinalysis with microscopy.

[[META_DIRECTIONS_START]] [] [[META_DIRECTIONS_END]]

⬅ Back to History